Core Viewpoint - The legal opinion letter from Beijing Jincheng Tongda (Shanghai) Law Firm confirms that Jiangxi Chenguang New Materials Co., Ltd. has obtained the necessary approvals and authorizations for the repurchase and cancellation of shares related to its employee stock ownership plan for the period 2024-2026, in compliance with relevant laws and regulations [1][9]. Group 1: Repurchase and Cancellation Details - The repurchase price for the shares to be canceled is set at 6.13 yuan per share plus the interest from bank deposits [6][7]. - A total of 660,032 shares will be repurchased due to the failure to meet performance targets for the first unlocking period of the employee stock ownership plan [6][7]. - The company has established a dedicated securities account for the repurchase and has applied for the necessary procedures with the China Securities Depository and Clearing Corporation [7]. Group 2: Performance Assessment - The performance assessment for the unlocking of shares is based on the growth rates of operating revenue and net profit compared to the previous year, specifically using 2023 as the base year [6]. - The company did not achieve the required performance targets for the first unlocking period, necessitating the repurchase of the corresponding unvested shares [6][7]. Group 3: Information Disclosure - The company has fulfilled its information disclosure obligations as required by the listing rules and relevant guidelines, including announcements regarding the board's resolutions and the status of the employee stock ownership plan [8][9]. - Continuous compliance with information disclosure requirements will be necessary as the incentive plan progresses [9]. Group 4: Legal Compliance - The legal opinion asserts that the repurchase and cancellation actions are in accordance with the Company Law, Securities Law, and relevant guidelines, ensuring that all necessary legal procedures have been followed [9].

江西晨光新材料股份有限公司 关于回购注销 2024-2026 年员工持股计划 部分股份的实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：根据《江西晨光新材料股份有限公司 2024-2026 年员工 持股计划（草案）》（以下简称"《员工持股计划（草案）》"）的相关规定及 江西晨光新材料股份有限公司（以下简称"公司"）层面业绩考核结果，公司 2024-2026 年员工持股计划（以下简称"本员工持股计划"）第一个解锁期解锁 条件未成就，需回购注销本员工持股计划持有人已获授但不得解锁的股份合计 660,032 股。 本次回购注销股份的有关情况 证券代码：605399 证券简称：晨光新材 公告编号：2025-028 | 回购股份数量（股） | 注销股份数量（股） | 注销日期 | | | | | --- | --- | --- | --- | --- | --- | | 660,032 | 660,032 | 年 月 2025 | 7 | 14 | 日 | 一、本员工持股计划回购注销的决策与信息披 ...

北京金诚同达（上海）律师事务所 关于 江西晨光新材料股份有限公司 2024-2026 年员工持股计划回购注销事项的 法律意见书 上海市浦东新区世纪大道88号金茂大厦18层 电话：86-21-3886 2288 传真：021-3886 2288*1018 北京金诚同达（上海）律师事务所 法律意见书 释 义 在本法律意见书内，除非文义另有所指，下列词语具有下述涵义： 1 北京金诚同达（上海）律师事务所 法律意见书 北京金诚同达（上海）律师事务所 关于江西晨光新材料股份有限公司 2024-2026 年员工持股计划回购注销事项的 法律意见书 金沪法意[2025]第 237 号 致：江西晨光新材料股份有限公司 本所接受公司的委托，担任晨光新材员工持股计划的专项法律顾问。根据《公 司法》《证券法》《指导意见》等有关法律、法规和规范性文件以及《公司章程》 的规定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对公司员工 持股计划所涉及的有关文件资料和事实进行了核查和验证，出具本法律意见书。 | 晨光新材、公司 | 指 | 江西晨光新材料股份有限公司 | | --- | --- | --- | | 员工持股计划、本员工 ...

Group 1 - The core viewpoint of the article highlights the strong performance of the organic silicon sector, driven by the explosive growth in the photovoltaic industry [1] - Companies such as Dongyue Silicon Materials and Hoshine Silicon Industry approached their daily limit up, while Silan Technology surged over 10% [1] - Other companies including Runhe Materials, Hongbai New Materials, Chenguang New Materials, and Xinyaqiang also experienced gains [1] Group 2 - The main driver of this surge is the significant increase in the futures market, with the main contract for polysilicon futures hitting the daily limit up, leading to an expansion of the industrial silicon futures main contract's increase to 5% [1]

Core Points - The stock price of Chenguang New Materials (605399) closed at 12.36 yuan on July 4, 2025, down 0.72% from the previous week [1] - The company has a total market capitalization of 3.867 billion yuan, ranking 108th out of 169 in the chemical products sector and 3702nd out of 5149 in the A-share market [1] Shareholder Changes - As of June 30, 2025, the number of shareholders decreased by 926, a reduction of 4.69% [1][3] - The average number of shares held per shareholder increased from 15,900 to 16,600 shares, with an average holding value of 212,300 yuan [1] Company Announcements - Chenguang New Materials received a government subsidy of 26 million yuan on June 27, 2025, which is related to revenue and accounts for 62.86% of the audited net profit attributable to shareholders for the fiscal year 2024 [1][3] - The subsidy is expected to have a positive impact on the company's net profit, with specific accounting treatment and effects to be confirmed by the annual audit [1]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

Group 1 - Taotao Automotive expects a net profit of 310 million to 360 million yuan for the first half of 2025, representing a year-on-year increase of 70.34% to 97.81% [1] - The company specializes in the research, production, and sales of all-terrain vehicles, electric golf carts, electric scooters, electric balance bikes, electric bicycles, and their accessories [1] - China Communications Construction Company plans to repurchase shares worth between 500 million to 1 billion yuan, with a maximum repurchase price of 13.58 yuan per share [1][2] Group 2 - Annoqi's subsidiary received a government subsidy of 1.65 million yuan, accounting for 34.77% of the company's latest audited net profit [2] - Annoqi focuses on the research, production, and sales of mid-to-high-end differentiated dyes [3] - Minfeng Special Paper announced the complete shutdown of its Nanhu plant, as its Haiyan plant is now capable of handling the production capacity [4] Group 3 - Aoto Electronics received a trademark registration certificate from Saudi Arabia, covering various electronic products [5] - Landi Group plans to acquire up to 20.1667% of the shares of Jujia Technology for a total price not exceeding 121 million yuan [6][7] - Lifan Pharmaceutical's Danpi phenol raw material drug has been approved for market launch, utilizing a new process that enhances efficiency and meets market demand [8] Group 4 - Shanghai Construction received a total of 548 million yuan in government subsidies, which accounts for 22.79% of the company's latest audited net profit [8] - Wanbangde's subsidiary received ethical approval for a key clinical trial of a new drug for Alzheimer's disease [8] - Prolo Pharmaceutical's subsidiary received approval for the market launch of a new raw material drug for liver cancer treatment [9] Group 5 - Chenguang New Materials received a government subsidy of 26 million yuan, representing 62.86% of the company's latest audited net profit [10] - Sanyou Medical's subsidiary received a government subsidy of 331,000 yuan, accounting for 28.86% of the company's latest audited net profit [11] - Weichai Heavy Machinery expects a net profit of 132 million to 151 million yuan for the first half of 2025, reflecting a year-on-year increase of 40% to 60% [12] Group 6 - Guanhao Biological announced the termination of its application for a specific stock issuance [13] - China Film plans to use up to 1.5 billion yuan of idle funds for cash management [14] - Aotai Biological intends to use up to 480 million yuan of idle raised funds for cash management [15] Group 7 - Helin Micro-Nano is planning to issue overseas shares and list on the Hong Kong Stock Exchange [17] - Jinpan Technology's vice president resigned due to personal health reasons [18] - Tongyi Zhong's chairman and general manager plan to reduce their shareholdings in the company [19] Group 8 - Naipu Mining signed an overseas contract worth 18.85 million USD [21] - Zhengye Technology completed an asset sale transaction worth 178 million yuan [23] - Lianxin Equipment won a bid for a project worth 157 million yuan from BOE [24] Group 9 - Smart Control plans to apply for a comprehensive credit line of up to 260 million yuan from banks [25] - Keyuan Pharmaceutical's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [27] - Meige Intelligent's H-share listing application materials have been received by the China Securities Regulatory Commission [29] Group 10 - Siwei Tuxin's subsidiary submitted an H-share listing application [32] - Metro Design's application for issuing shares to purchase assets has been accepted by the Shenzhen Stock Exchange [32] - Aeston submitted an application for H-share listing [34] Group 11 - Jiu Ri New Materials' shareholders plan to reduce their holdings by a total of 98,900 shares [34] - Yihua Tong's shareholder plans to reduce their holdings by up to 700,000 shares [35] - Xishanghai plans to distribute a cash dividend of 0.08 yuan per share [36] Group 12 - Zhejiang Natural plans to distribute a cash dividend of 1.97 yuan for every 10 shares [37] - Kouzi Jiao plans to distribute a cash dividend of 1.30 yuan per share [38] - Huitong Group plans to distribute a cash dividend of 0.023 yuan per share [40] Group 13 - Tongyong Co. plans to reduce its holdings by up to 0.31% of the company's shares [41] - China Shenhua plans to distribute a cash dividend of 2.26 yuan for every 10 shares [43] - Huangting International's executive director resigned due to personal reasons [45] Group 14 - Jinkai New Energy plans to distribute a cash dividend of 1 yuan for every 10 shares [46] - Heimu Dan plans to distribute a cash dividend of 0.041 yuan per share [47] - Feiyada plans to acquire all or part of the controlling stake in Chang Kong Gear [48]

证券代码：605399 证券简称：晨光新材 公告编号：2025-027 江西晨光新材料股份有限公司 二、补助的类型及其对上市公司的影响 根据《企业会计准则第 16 号——政府补助》等有关规定，上述补助属于与 收益相关的补助，确认为当期损益，预计将对公司净利润产生一定的积极影响， 具体的会计处理以及对公司损益的影响情况以会计师事务所年度审计确认后的 结果为准，请广大投资者注意投资风险。 特此公告。 江西晨光新材料股份有限公司董事会 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 江西晨光新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日 收到 2,600 万元人民币与收益相关的政府补助，占公司 2024 年度经审计归属于 上市公司股东净利润的 62.86%。 2025 年 6 月 30 日 ...

智通财经6月30日电，晨光新材(605399.SH)公告称，公司于2025年6月27日收到2600万元人民币与收益 相关的政府补助，占公司2024年度经审计归属于上市公司股东净利润的62.86%。该补助预计将对公司 净利润产生一定的积极影响。 晨光新材：收到2600万元政府补助 ...

Core Insights - The company, Morning Light New Materials (晨光新材), reported a decline in both revenue and profit for the year 2024, with total revenue of 1.16 billion yuan, down 0.42% year-on-year, and a net profit attributable to shareholders of 41.36 million yuan, down 59.14% year-on-year [1][2]. Financial Performance - The gross profit margin for 2024 was 14.84%, a decrease of 0.31% compared to the previous year, while the net profit margin was 3.53%, down 5.14% year-on-year [2]. - The company incurred total operating expenses of 132 million yuan, an increase of 22.44 million yuan year-on-year, resulting in an expense ratio of 11.38%, up 1.97% from the previous year [2]. - Sales expenses increased by 12.96%, management expenses rose by 13.25%, while research and development expenses decreased by 9.95%, and financial expenses surged by 44.50% [2]. Employee Statistics - As of 2024, the total number of employees in the company was 1,372, reflecting an increase of 132 employees or 10.65% compared to the previous year [3]. Executive Compensation - The total remuneration for the board of directors, supervisors, and senior management in 2024 amounted to 8.92 million yuan, with the chairman receiving 1.17 million yuan and the general manager receiving 1.43 million yuan [5][6]. Company Background - Morning Light New Materials, established on September 29, 2006, is located in Jiujiang, Jiangxi Province, and specializes in the research, production, and sales of functional silane basic raw materials, intermediates, and finished products [7].